Comparison of the effect of allopurinol and febuxostat on 2,8-dihydroxyadenine in plasma and urine: a clinical trial
The plasma concentration and urinary excretion of DHA decreased markedly on treatment with both study drugs, although febuxostat was more efficacious than allopurinol in both prescribed doses. Trial registration number and date of registration. EudraCT No. 2021-002185-40; https://www.clinicaltrialsregister.eu/ctr-search/search?query=Research+Registry Date on which this record was first entered in the EudraCT database: 2019-03-19.
Authors
- Hrafnhildur L. Runolfsdottir (ORCID: https://orcid.org/0000-0003-1826-1383)
- Viðar Ö. Eðvarðsson (ORCID: https://orcid.org/0000-0002-4204-9342)
- Margrét Þorsteinsdóttir (ORCID: https://orcid.org/0000-0002-0649-8503)
- Runólfur Pálsson (ORCID: https://orcid.org/0000-0001-6763-1702)
- Thorunn Oskarsdottir
- Inger M. Sch. Agustsdottir
- Unnur A. Thorsteinsdottir (ORCID: https://orcid.org/0000-0002-8198-7948)
- Sigrun Alba Johannesdottir
Institutions
- Reykjavík University (IS)
- University of Iceland (IS)
- National University Hospital of Iceland (IS)
- Icelandic Transport Authority (IS)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1007/s40620-025-02392-5
- Citations
- 2
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Icelandic Centre for Research